Myriad Genetics has appointed Chip Parkinson as executive vice president for reimbursement strategy. He will report to President and CEO Mark Capone. Parkinson comes to Myriad from Cambia Health Solutions where he served as president of OmedRx and MedSavvy, and as chief pharmacy officer for Regence Blue Cross Blue Shield Health Plans. He has also served in general management and managed care leadership roles at Pfizer and Myriad.
3D Signatures has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the company's board of directors. Flowerday has more than a decade of business development and marketing experience in the life sciences, including leadership experience at Bayer and Johnson and Johnson. He has also held executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio. Additionally, Flowerday was co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications, and he is an independent director of Aequus Pharmaceuticals.
Opko Health has appointed Benjamin Solomon as managing director of GeneDx, part of Opko's BioReference Laboratories subsidiary. Solomon comes to Opko from Inova Translational Medicine Institute, where he most recently served as chief of the division of medical genomics. He attended medical school at Geisel School of Medicine at Dartmouth College and completed his residency and fellowship training in pediatric medicine and clinical genetics at the National Human Genome Research Institute and at Children's National Medical Center. Solomon is a board-certified pediatrician in clinical genetics and pediatrics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.